Browsing by Autor "Liliana Mojica-Balceras"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    Item type: Item ,
    Consenso de leucemia mieloide aguda en México
    (Academia Nacional de Medicina de México, 2022) Luara L. Arana-Luna; Martha Alvarado‐Ibarra; Luis G. Silva-Michel; Adrián Morales-Maravilla; María del C. González-Rubio; Lénica A. Chávez-Aguilar; Ma. Fernanda Tena-Iturralde; Liliana Mojica-Balceras; Nidia Zapata-Canto; Patricia Galindo-Delgado
    Acute myeloid leukemia (AML) comprises a heterogeneous group of hematopoietic cell neoplasms of myeloid lineage that arise from the clonal expansion of their precursors in the bone marrow, interfering with cell differentiation, leading to a syndrome of bone marrow failure. AML is a consequence of genetic and epigenetic changes (point mutations, gene rearrangements, deletions, amplifications, and arrangements in epigenetic changes that influence gene expression) in hematopoietic precursor cells, which create a clone of abnormal cells that are capable of proliferating but cannot differentiate into mature hematopoietic cells or undergo programmed cell death. The diagnosis requires more than 20% myeloid blasts in the bone marrow and certain cytogenic abnormalities. Treatment will depend on age, comorbidities, and cytogenetic risk among the most frequent.